Sign in

You're signed outSign in or to get full access.

PB

PUMA BIOTECHNOLOGY, INC. (PBYI)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 delivered resilient top-line and stronger profitability: total revenue $59.1M (product $54.4M; royalty $4.7M), GAAP EPS $0.39 and non-GAAP EPS $0.43; royalty downswing (China timing) was offset by higher U.S. demand and a ~$3.7M inventory build at distributors and specialty pharmacies .
  • FY25 outlook introduced: net product revenue $192–$198M, royalties $20–$24M, net income $23–$28M, gross-to-net 20.5%–21.5%; Q1’25 guide embeds seasonal inventory burn (net product revenue $41–$43M, royalties $1.5–$2.5M, gross-to-net 22.5%–23.5%, net loss $(2)–$0M) .
  • Commercial execution: 2,964 NERLYNX bottles (+9% q/q; ~205 bottle inventory build), dose-escalation adoption ~74%, and ex-U.S. approvals/launches (Turkey, Thailand, Saudi Arabia) support demand quality and persistence initiatives .
  • Pipeline and external catalysts: interim readouts expected in H1’25 for NCI Enhertu+neratinib Phase 1 and later in 2025 for ALISCA-Breast1 and ALISCA-Lung1; NCCN added neratinib (monotherapy) as 2L+ in HER2-mutated cervical cancer (Cat 2A) in Dec-2024, a potential awareness tailwind .
  • Accounting tailwind: a $7.1M deferred tax valuation allowance release boosted Q4 net income and EPS; management reiterated discipline to sustain positive net income in 2025 despite lower China-related royalties in the near term .

What Went Well and What Went Wrong

What Went Well

  • Positive net income for third consecutive year, aided by disciplined OpEx and portfolio execution; Q4 GAAP EPS $0.39 and non-GAAP EPS $0.43; FY25 guide calls for continued profitability (net income $23–$28M) .
  • Commercial execution improved: bottles +9% q/q to 2,964 with ~205 bottle inventory build; dose-escalation started in ~74% of patients supports persistence/compliance benefits and helps manage tolerability .
  • Ex-U.S. momentum and guideline expansion: ex-U.S. approvals/launches (Turkey, Thailand, Saudi Arabia) and NCCN add neratinib as 2L+ option in HER2-mutated cervical cancer (Cat 2A), potentially broadening awareness and access .

What Went Wrong

  • Royalties fell to $4.7M from $24.4M in Q3 on China shipment timing; management expects 2025 royalties to be lower ($20–$24M vs. 2024) and lumpy as regulatory transitions complete .
  • Gross-to-net rose to ~18.2% in Q4 from 17.1% in Q3, and Q1’25 gross-to-net is guided higher (22.5%–23.5%), pressuring net revenue in the near term .
  • Near-term seasonal/structural headwinds: Q1’25 guided to $(2)–$0M net income on typical Q4 inventory burn-off; demand in 2024 declined ~9–10% y/y (mgmt aims to limit 2025 demand decline to ~2%) .

Financial Results

Revenue and EPS vs prior periods

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Total Revenue ($M)$72.2 $47.1 $80.5 $59.1
Product Revenue, net ($M)$53.2 $44.4 $56.1 $54.4
Royalty Revenue ($M)$19.0 $2.7 $24.4 $4.7
GAAP Diluted EPS ($)$0.26 $(0.09) $0.41 $0.39
Non-GAAP Diluted EPS ($)$0.31 $(0.05) $0.45 $0.43

Notes: Q4 2024 product revenue impacted by ~$3.7M inventory build; royalties lower due to China shipment timing .

Operating P&L line items (select)

Metric ($M)Q4 2023Q4 2024
Cost of Sales$24.3 $13.9
SG&A$20.2 $16.6
R&D$12.9 $15.2
Income from Operations$14.8 $13.4
Deferred Tax Benefit$— $7.1

Commercial and cash KPIs

KPIQ3 2024Q4 2024
NERLYNX bottles sold (ex-factory)2,723 2,964
Inventory build (bottles)+37 +205
Inventory build ($)+$0.6M +$3.7M
NRx change (q/q)—~–7%
TRx change (q/q)—~+4%
Gross-to-net (%)17.1% ~18.2%
Product supply revenue ($M)$7.4 $0.8
Cash, cash equivalents & marketable securities ($M)~$97 (9/30/24) ~$101 (12/31/24)
Total principal debt (approx.) ($M)~$—~$67

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Net Product RevenueQ1 2025—$41–$43M New
Royalty RevenueQ1 2025—$1.5–$2.5M New
Gross-to-NetQ1 2025—22.5%–23.5% New
Net Income/(Loss)Q1 2025—$(2)–$0M New
Net Product RevenueFY 2025—$192–$198M New
Royalty RevenueFY 2025—$20–$24M New
Gross-to-NetFY 2025—20.5%–21.5% New
Net IncomeFY 2025—$23–$28M New
SG&AFY 2025—Down 5%–10% y/y (qualitative) New
R&DFY 2025—Up 10%–15% y/y (qualitative) New
Net Product RevenueFY 2024$183–$190M (prior) → $187–$190M (new) Actual $195.2M Raised in Nov; actual above new guide
Royalty RevenueFY 2024$30–$34M (prior) → $34–$36M (new) Actual $35.3M Raised in Nov; actual within range
License RevenueFY 2024$1–$2M (unchanged) Actual $0M Below guide
Net IncomeFY 2024$12–$15M (prior) → $15–$17M (new) Actual $30.3M (incl. $7.1M tax benefit) Raised in Nov; actual above (tax benefit)
Gross-to-NetFY 202421%–22% (prior) → 20.5%–21.5% (new) 2024 not explicitly stated; Q4 ~18.2% Lowered in Nov

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024, Q3 2024)Current Period (Q4 2024)Trend
China royalties/shipmentsQ2: Royalties $2.7M (low) ; Q3: Royalties $24.4M (China bolus) Q4: Royalties $4.7M; expect lower/lumpy in 2025 during regulatory transition Volatile/lower near term
Gross-to-netQ2 guide FY24 21%–22% ; Q3 guide FY24 trimmed to 20.5%–21.5% Q4 ~18.2%; Q1’25 22.5%–23.5%; FY25 20.5%–21.5% Near-term uptick in Q1, normalize FY
Demand/persistence & dose escalationQ3: Non-personal/personal promo, execution focus 74% started at reduced dose; 5–10% more patients remain on therapy when started lower; NRx –7% q/q; TRx +4% q/q Improving persistence; mixed demand seasonality
Ex-U.S. expansionNoted distribution partners; international royalties growth in Q3 Approvals (Turkey, Thailand) and launch (Turkey, Saudi Arabia) Expanding footprint
Pipeline (alisertib; combos)Q2: ASCO data; ALISCA-Breast1 initiation expected Q4 ALISCA-Breast1 initiated Nov; enrollment ahead; interim in 2025; NCI Enhertu+neratinib interim in H1’25 Execution vs. plan on track
Pricing/reimbursement (IRA Part D)—Minimal impact seen so far on Medicare trends Stable early read

Management Commentary

  • “We are very pleased…to report positive net income for the third consecutive year, reflecting our strong execution and disciplined financial management” .
  • “Product revenue for the fourth quarter…was impacted by approximately $3.7 million of inventory increase at our specialty pharmacies and distributors” .
  • “Royalty revenue totaled $4.7 million…lower…as our partner works through regulatory transitions [in China] during the first several quarters of 2025” .
  • “In the fourth quarter of 2024, we released a portion of our valuation allowance, resulting in a non-cash deferred tax income benefit of $7.1 million” .
  • “In Q4, approximately 74% of patients started NERLYNX at a reduced dose…we see now about a 5% to 10% more patients remaining on therapy if you start at a lower dose” .

Q&A Highlights

  • Enhertu (trastuzumab deruxtecan) + neratinib Phase 1 interim data targeted for H1’25 (submitted to AACR or ASCO); disclosure likely at a medical conference .
  • Demand vs. price in 2025: 7% price increase taken in early Q1’25; planning for ~2% demand decline vs. ~9–10% decline in 2024; aim to outperform .
  • China royalties expected to be lumpy and lower in 2025 due to registration transfer; in-market demand remains on track without reduction .
  • IRA Part D redesign: no significant reimbursement/persistence impact observed to date in Medicare cohort .
  • ALISCA-Breast1 interim: expect early response/duration signals with dose-ranging (30/40/50 mg) per Project Optimus; TBCRC 041 (50 mg) serves as efficacy bar; fuller dataset will take time .

Estimates Context

  • S&P Global consensus EPS and revenue for Q4 2024 and prior quarters were not retrievable during this session due to a temporary request limit; as a result, we do not present “vs. consensus” comparisons in this report. The press release and call did not state consensus or explicit beats/misses .
  • Implication: Street models may adjust for (i) royalty step-down vs. Q3 (China timing), (ii) higher Q1’25 gross-to-net and seasonal inventory burn, (iii) 7% U.S. price increase, and (iv) FY25 royalty guidance reset to $20–$24M .

Key Takeaways for Investors

  • Mix shift and timing matter: Q4 royalties fell sharply on China shipment timing; 2025 royalties guided lower/lumpy as registration transitions, but U.S. demand and price action should partially offset .
  • Profit discipline continues: despite royalty variability, management guides to FY25 net income of $23–$28M with SG&A down 5–10% and R&D up 10–15% to support alisertib .
  • Near-term setup: Q1’25 is seasonally weakest (inventory burn) with higher gross-to-net, guiding to breakeven/$(2)M; watch inventory normalization into Q2 .
  • Commercial quality improving: dose-escalation strategy supports persistence/compliance; Q4 TRx +4% q/q and bottles +9% q/q; monitor NRx reacceleration into 1H’25 .
  • Ex-U.S. catalysts: new approvals/launches and NCCN cervical cancer inclusion could expand the addressable opportunity and awareness over time .
  • Clinical catalysts: H1’25 Enhertu+neratinib interim and 2025 alisertib readouts are key potential stock movers, alongside updates on China royalty cadence .
  • Accounting tailwind in Q4 (valuation allowance release) boosted EPS; underlying run-rate should be assessed excluding this non-cash benefit .

Supporting Detail

Additional revenue composition (quarterly)

MetricQ2 2024Q3 2024Q4 2024
Gross NERLYNX Sales ($M)——$66.5
Net Product Revenue ($M)$44.4 $56.1 $54.4
Product Supply Revenue ($M)—$7.4 $0.8
Royalty Revenue ($M)$2.7 $24.4 $4.7
Gross-to-Net (%)18.5%–19.5% (Q3 guide) 17.1 ~18.2

Balance sheet and cash flow (year-end)

MetricFY 2023FY 2024
Cash & Cash Equivalents ($M)$84.6 $69.2
Marketable Securities ($M)$11.4 $31.7
Working Capital ($M)$56.8 $51.5
Short-term Debt ($M)$34.0 $45.3
Long-term Debt ($M)$65.7 $21.7
Stockholders’ Equity ($M)$53.4 $92.1
Cash from Operations ($M)$27.0 $38.9

Select qualitative disclosures

  • Distribution channel split ~75% SP / 25% SD; added BioCare to SD network; ~4 weeks of inventory in channel at year-end .
  • Q4 seasonality: enrollments and new patient starts soften as patients defer initiation until after holidays; seen again in Q4’24 .

All citations:

  • Q4 2024 8-K (press release and financials): .
  • Q4 2024 earnings call: .
  • Q3 2024 press release: .
  • Q2 2024 press release: .
  • NCCN cervical cancer update: .